29335-36-2

Basic information

• Product Name: N-HYDROXYPROPIONAMIDINE
• Synonyms: AKOS B030359;N-HYDROXYPROPIONAMIDINE;Propionamidoxime;(1Z)-N'-hydroxypropanimidamide hydrochloride;propanimidamide, N'-hydroxy-, (1Z)-;(1Z)-N'-hydroxypropanimidamide(SALTDATA: HCl);(1Z)-N'-hydroxypropanimidamide 1HCl;N'-hydroxypropaniMidaMide
• CAS NO: 29335-36-2
• Molecular Formula: C₃H₈N₂O
• Molecular Weight: 88.11
• Product Categories: pharmacetical
• Mol File: 29335-36-2.mol
• Article Data: 29

Chemical Properties

• Boiling Point: 205.1°Cat760mmHg
• Flash Point: 77.8°C
• Appearance: /
• Density: 1.12g/cm³
• Vapor Pressure: 0.0608mmHg at 25°C
• Refractive Index: 1.475
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 7.48±0.69(Predicted)
• Water Solubility: Slightly soluble in water.
• Sensitive: Hygroscopic
• CAS DataBase Reference: N-HYDROXYPROPIONAMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: N-HYDROXYPROPIONAMIDINE(29335-36-2)
• EPA Substance Registry System: N-HYDROXYPROPIONAMIDINE(29335-36-2)

Safety Data

• Hazard Codes: T
• Statements: 36/37/38-25
• Safety Statements: 26-36/37/39-45
• RIDADR: UN3267
• HazardClass: 8
• PackingGroup: III
• Hazardous Substances Data: 29335-36-2(Hazardous Substances Data)

Usage

Uses

Propionamidoxime is used as pharmaceutical intermediate.

InChI:InChI=1/C3H8N2O/c1-2-3(4)5-6/h6H,2H2,1H3,(H2,4,5)

Upstream product

• 107-12-0 propiononitrile 
• 1738-36-9 2-methoxyacetonitrile 

Downstream Products

• 92676-39-6 FG 8006 
• 146422-57-3 5-(3-Ethyl-[1,2,4]oxadiazol-5-yl)-1-trityl-1,4,5,6-tetrahydro-pyrimidine 
• 50737-34-3 5-chloromethyl-3-ethyl-[1,2,4]oxadiazole 
• 173303-02-1 2-(2,5-dimethylphenoxymethyl)phenyl 3-ethyl-1,2,4-oxadiazol-5-yl ketone O-methyloxime 
• 96136-77-5 5-(3-chlorobenzyloxy)-3-(5'-(3'-ethyl-(1,2,4-oxadiazol))yl)-4-methoxymethyl-β-carboline 
• 109623-69-0 5-(4-chlorophenoxy)-3-(3-ethyl-1,2,4-oxadiazol-5-yl)-4-methoxymethyl-β-carboline 
• 101151-34-2 3-[5-(3-ethyl-1,2,4-oxadiazole)-yl]-4-methoxymethyl-5-benzyloxy-β-carboline 
• 1046536-29-1 C₁₈H₃₁N₃O₄ 
• 612526-74-6 5-(8-ethynyl-6-phenyl)-4H-benzo-[f]-imidazo-[1,5-a]-[1,4]-diazepine-3-ethyl-1,2,4-oxadiazole 
• 22354-96-7 3-ethyl-5-phenyl-1,2,4-oxadiazole 

Relevant articles and documents

Process research towards a scalable synthesis of the muscarinic M 1 receptor subtype selective agonist MCD-386

An efficient process for the M1-selective muscarinic agonist MCD-386 has been developed that offers significant advantages over the original synthetic approach. The new process utilizes an improved preparation of a known symmetrical diamine ester, followed by elaboration to a symmetrical 5-substituted tetrahydropyrimidine. The new route avoids cryogenics and chromatography steps, circumvents an expensive protecting group strategy, and offers significant improvements in cost and throughput.

Discovery and Structure-Activity-Relationship Study of N-Alkyl-5-hydroxypyrimidinone Carboxamides as Novel Antitubercular Agents Targeting Decaprenylphosphoryl-β-D-ribose 2′-Oxidase

Magnesium plays an important role in infection with Mycobacterium tuberculosis (Mtb) as a signal of the extracellular environment, as a cofactor for many enzymes, and as a structural element in important macromolecules. Raltegravir, an antiretroviral drug

Substituted aminopyrimidine compounds and their method and use thereof

The invention relates to a new aminopyrimidine compound and an application thereof as a drug for treating disorder or diseases related to PI3-kinase abnormity in a free form or a pharmaceutically acceptable salt and preparation form. The invention also relates to a pharmaceutical composition which contains the new aminopyrimidine compound and an application of the pharmaceutical composition in treating mammal disorder or diseases and especially treating human disorder or diseases related to the PI3-kinase abnormity, such as treatment of immunity and inflammatory diseases of PI3-kinase regulation which plays a leading role in a leucocyte function and treatment of proliferative diseases which are related to PI3-kinase activity and include but not limited to leukaemia and solid tumor.